Stock market technical analysis forecast | Nasdaq trend research for trading investing | 401k
trading penny stock breakout day investing
Skip Navigation Links
    Home
    •   About US
    Market Activity
    World Indices
    Market Watch
    Customer Service
    Learning Center
    Economic Event
    Login


Join Now




Advertise 2 ۩  Daily market forecast

Hot Penny Stock picks for investing - support resistance research

BBI Blockbuster Inc (BBI)
Sector 
RecommendationsBuy
Buy Near0.76
Stop Loss0.70
Posted Date1/18/2010 12:00:00 AM
First resistance0.92
Second resistance1.03
Third resistance1.38
First Support0.60
Second Support0.62
Comments
1/18/2010 12:00:00 AM0) Blockbuster Inc (BBI) is a leading global provider of rental and retail movies and games
1) This penny Stock company (BBI) provides customers with convenient access to media entertainment anywhere, any way they want it - whether in-store, by-mail, through vending kiosks or digitally downloaded directly to their family room or mobile device
2) Blockbuster Inc (BBI) have library of more than 125,000 movies and games
3) Blockbuster Inc (BBI) recently announced that it has eliminated the final $24 million of certain letters of credit it maintained on behalf of its former parent company, Viacom Inc and this stapes naturally increase the liquidity of cash, again Blockbuster Inc (BBI) raised $675 million on our bond offering to extend our debt maturities into 2014

As per technical analysis of this penny Stock ADX and Stockhastic given a buy signal and it Started up trend with RSI positive divergence and recently it breakout with very high volume
4) Recent company’s action also supporting our positive view, so Blockbuster Inc (BBI) you can consider for breakout penny Stock portfolio, and you can enter near $0.76 with $0.60 stop loss
5) This Stock trading with high volume so you can consider for penny Stock day trading also
6)

DM crossover and raising ADX with Stockhastic buy signal and breakout with high volume and sustain breakout point on following day is a ideal condition to buy Stock and in this penny Stock you found all this factors, still keep stop loss because penny Stock when turn negative we never know, so protect your investment stop loss is important
7)
BBI
Brickell Biotech to Participate in March Virtual Investor Conferences
(Thu, 25 Feb 2021 21:05:00 +0000)
BOULDER, Colo., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that Robert Brown, Brickell’s Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference and participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference, which are both being held in March 2021. Details are as follows: Conference: H.C. Wainwright Global Life Sciences Conference (virtual)Date: Tuesday, March 9, 2021Time: 7:00 AM ESTManagement will be available throughout the day on March 10th for virtual one-on-one meetings. Conference: Oppenheimer 31st Annual Healthcare Conference (virtual)Date: Thursday, March 18, 2021Time: 8:00 AM EDTManagement will be available throughout the day on March 17th and 18th for virtual one-on-one meetings. Webcasts of the presentation at the H.C. Wainwright Global Life Sciences Conference and of the fireside chat at the Oppenheimer 31st Annual Healthcare Conference will be available in the Investors section of the Brickell website at https://ir.brickellbio.com/events-presentations. The webcasts of both events will remain archived on the Brickell website for approximately 90 days. About Brickell Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs. For more information, visit https://www.brickellbio.com. Brickell Investor Contact:Dan FerryLifeSci Advisors(617) 430-7576daniel@lifesciadvisors.com
Brickell Biotech to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on March 9, 2021
(Tue, 23 Feb 2021 21:01:00 +0000)
BOULDER, Colo., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2020, after the market close on Tuesday, March 9, 2021. Brickell’s management will host a conference call and webcast at 4:30 pm ET on Tuesday, March 9th to discuss the financial results and recent corporate highlights. To access the call, please dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. and provide the conference ID number: 13715394. To access the live webcast, please go to the Investors section of Brickell’s website at https://ir.brickellbio.com/events-presentations. Following the live webcast, an archived version of the call will be available on the website. About Brickell Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs. For more information, visit https://www.brickellbio.com. Brickell Investor Contact:Dan FerryLifeSci Advisors(617) 430-7576daniel@lifesciadvisors.com
Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology
(Tue, 19 Jan 2021 12:00:00 +0000)
Commercial launch of ECCLOCK® in Japan currently underway by Development Partner, Kaken PharmaceuticalBOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that the efficacy and safety results from the pivotal Phase 3 study conducted in Japan by its development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”) were published in the peer-reviewed Journal of Dermatology1. The paper, entitled “A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis,” is available online in English at the Wiley Online Library (click here). Kaken and Brickell first announced the release of the Japan pivotal Phase 3 study results in June 2020. Subsequently, Kaken received regulatory approval to manufacture and market ECCLOCK® in Japan for the treatment of primary axillary hyperhidrosis in September 2020 and launched commercial sales in November 2020. Japan is the first country to approve sofpironium bromide, which also marks the first approval of a topical prescription product for the treatment of primary axillary hyperhidrosis in Japan. “We are pleased to see Kaken continue to advance the commercialization of ECCLOCK® in Japan, as a potential best-in-class treatment for patients with primary axillary hyperhidrosis,” said Deepak Chadha, Chief Research and Development Officer of Brickell. “The publication of Kaken’s pivotal Phase 3 study results in the highly regarded peer-reviewed Journal of Dermatology provides additional clinical support for sofpironium bromide and will be an important reference tool for treating dermatologists and physicians across Japan.” In addition, Brickell recently initiated its U.S. pivotal Phase 3 clinical program evaluating sofpironium bromide gel, 15% for the treatment of primary axillary hyperhidrosis. Brickell expects to report topline data from the U.S. pivotal Phase 3 program in the fourth quarter of 2021. About Sofpironium Bromide Sofpironium bromide is a proprietary investigational new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action locally and are potentially rapidly metabolized into a less active metabolite once absorbed into the blood. Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida. About Hyperhidrosis Hyperhidrosis is a life-altering medical condition where a person sweats more than the body requires to regulate its temperature. More than 15 million people, or 4.8% of the population of the United States, and 12.76% of the population in Japan, are believed to suffer from hyperhidrosis2,3. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States. Additional information can be found on the International Hyperhidrosis Society website: https://www.sweathelp.org/. About Brickell Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit https://www.brickellbio.com. Cautionary Note Regarding Forward-Looking Statements Any statements made in this press release relating to future financial, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the anticipated timing, scope, design, progress and/or results of ongoing and future clinical trials, intellectual property rights, including the validity, term and enforceability of such, the expected timing and/or results of regulatory submissions and approvals, and prospects for commercializing any of Brickell’s product candidates, or research collaborations with, or actions of, its partners, including in Japan, the United States or any other country, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict,” “potential,” “look forward” and similar expressions and their variants, as they relate to Brickell, Kaken, or any of Brickell’s partners, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, ability to obtain adequate financing to advance product development, ability to maintain and enforce intellectual property rights, potential delays for any reason in product development, regulatory changes, supply chain disruptions, unanticipated demands on cash resources, any disruption to its business caused by the current COVID-19 pandemic, interruptions, disruption or inability by Kaken to supply and commercialize the product in Japan, or obtain or retain adequate pricing or reimbursement, and other risks associated with developing, and obtaining regulatory approval for and commercializing product candidates. Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States Securities and Exchange Commission (SEC), which are available at https://www.sec.gov (or at https://www.brickellbio.com). The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements. 1 The Journal of Dermatology is the official peer-reviewed publication of the Japanese Dermatological Association and the Asian Dermatological Association.2 Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749.3 Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90. Brickell Investor Contact:Dan FerryLifeSci Advisors(617) 430-7576daniel@lifesciadvisors.com
Reflecting on Brickell Biotech's (NASDAQ:BBI) Share Price Returns Over The Last Year
(Wed, 06 Jan 2021 05:50:17 +0000)
Brickell Biotech, Inc. ( NASDAQ:BBI ) shareholders will doubtless be very grateful to see the share price up 75% in the...
Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study
(Mon, 07 Dec 2020 12:30:00 +0000)
Topline results from the U.S. pivotal Phase 3 program anticipated in the fourth quarter of 2021 Sofpironium bromide gel, 5% (ECCLOCK®) recently launched in Japan by development partner, Kaken PharmaceuticalBOULDER, Colo., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced dosing of the first patient in its second U.S. pivotal Phase 3 clinical study (“Cardigan II study”) evaluating sofpironium bromide gel, 15% in approximately 350 subjects aged nine and older with primary axillary (underarm) hyperhidrosis. Brickell’s U.S. Phase 3 program is comprised of two pivotal trials, the Cardigan I and Cardigan II studies, which are both currently enrolling patients. The Company expects to announce topline results from these two studies in the fourth quarter of 2021. If successful, the results from the studies are expected to form the basis of a prospective New Drug Application in the U.S. for sofpironium bromide gel, 15% for the treatment of primary axillary hyperhidrosis. Additional details of the Cardigan II study can be found on https://clinicaltrials.gov under identifier NCT03948646.“We are excited to announce the initiation of the Cardigan II study, which is the second trial in our U.S. pivotal Phase 3 clinical program for sofpironium bromide gel, 15%,” said Deepak Chadha, Chief Research and Development Officer of Brickell. “This marks another important milestone for the Company, and we continue to be encouraged by the progress we are making with our Phase 3 program, particularly in light of the current environment. We look forward to providing enrollment updates for the Cardigan I and II studies in the coming months.”On November 26, 2020, Brickell’s Japanese development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”) launched commercial sales of ECCLOCK® in Japan for the once-daily treatment of primary axillary hyperhidrosis. This marks the first commercialization of sofpironium bromide worldwide. Under the sublicense agreement with Kaken, Brickell is entitled to receive sales-based milestone payments, as well as tiered royalties based on a percentage of net sales of sofpironium bromide gel in Japan. Furthermore, Kaken has rights to develop and commercialize sofpironium bromide in South Korea, China, and certain other Asian countries, and Brickell is entitled to receive royalties based on a percentage of Kaken’s net sales in these countries.About Sofpironium BromideSofpironium bromide is a proprietary investigational new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action locally and are potentially rapidly metabolized into a less active metabolite once absorbed into the blood. Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida.About HyperhidrosisHyperhidrosis is a life-altering medical condition where a person sweats more than the body requires to regulate its temperature. More than 15 million people, or 4.8% of the population of the United States, and 12.76% of the population in Japan, are believed to suffer from hyperhidrosis1,2. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States. Additional information can be found on the International Hyperhidrosis Society website: https://www.sweathelp.org/.About BrickellBrickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit https://www.brickellbio.com.Cautionary Note Regarding Forward-Looking StatementsAny statements made in this press release relating to future financial, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the anticipated timing, scope, design, progress and/or results of ongoing and future clinical trials, intellectual property rights, including the validity, term and enforceability of such, the expected timing and/or results of regulatory submissions and approvals, and prospects for commercializing any of Brickell’s product candidates, or research collaborations with, or actions of, its partners, including in Japan, the United States or any other country, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict,” “potential,” “look forward” and similar expressions and their variants, as they relate to Brickell, Kaken, or any of Brickell’s partners, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, ability to obtain adequate financing to advance product development, ability to maintain and enforce intellectual property rights, potential delays for any reason in product development, regulatory changes, supply chain disruptions, unanticipated demands on cash resources, any disruption to its business caused by the current COVID-19 pandemic, interruptions, disruption or inability by Kaken to supply and commercialize the product in Japan, or obtain or retain adequate pricing or reimbursement, and other risks associated with developing, and obtaining regulatory approval for and commercializing product candidates.Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States Securities and Exchange Commission (SEC), which are available at https://www.sec.gov (or at https://www.brickellbio.com). The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.1Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749. 2 Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90.Brickell Investor Contact: Dan Ferry LifeSci Advisors (617) 430-7576 daniel@lifesciadvisors.com
HCKT Hackett Group, Inc
SectorServices
RecommendationsBuy
Buy Near2.12
Stop Loss1.88
Posted Date6/6/2009 1:32:46 AM
First resistance3.04
Second resistance3.38
Third resistance5.44
First Support2.00
Second Support1.88
Comments
6/6/2009 3:45:25 PM0) Penny Stock Alert - Hackett Group, Inc
1) (HCKT) is a global strategic advisory firm and company is a leader in best practice advisory, benchmarking, and transformation consulting services, including shared services, outsourcing and off shoring advice
2) Hackett business application consulting services helps costumer to maximize returns on IT investments At the end of the first quarter of 2009, the Hackett Group, Inc
3) (HCKT) got cash balance $26.3 million, and as per company Stock repurchase plan, the Company already repurchased approximately 1.0 million shares at average price $2.08 per share, for a total cost of $2.1 million
4) And still approximately $4.8 million remained available under the Company’s share repurchase program.

Based on the current economic Outlook, the Hackett Group, Inc
5) (HCKT) estimates total revenue for the second quarter of 2009 to be in the range of $34.0 M to $36.0 M and estimates earnings per share to be in the range of $0.00 to $0.03. Recently Wipro Technologies (WIT) announced they partnered with Oracle for best-of-breed HR platform solutions and for that Wipro has also selected The Hackett Group (HCKT), to provide empirical data, best practices and world-class Performance insights on the development of its innovative bundled solution platform
6) The solution, allows employers to reduce and control cost as it provides an opportunity to centralize and standardize processes while eliminating duplicative management structures
7)

As per chart analysis Hackett Group, Inc
8) (HCKT) Relative Strength (RSI) started to strengthening, rate of change also got good moment again there are strong demand closer to $2.12 that indicating accumulation going on, with good capital in hand and suitable to present economy business model offering over all best penny Stock investing option
9)
HCKT
Can Hackett Group (HCKT) Run Higher on Rising Earnings Estimates?
(Fri, 26 Feb 2021 17:20:05 +0000)
Hackett Group (HCKT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Hackett Group (HCKT) Upgraded to Buy: Here's What You Should Know
(Fri, 26 Feb 2021 17:00:05 +0000)
Hackett Group (HCKT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
HCKT vs. NVEE: Which Stock Should Value Investors Buy Now?
(Fri, 26 Feb 2021 16:40:04 +0000)
HCKT vs. NVEE: Which Stock Is the Better Value Option?
A Look Into Hackett Group's Price Over Earnings
(Wed, 24 Feb 2021 14:52:20 +0000)
In the current session, The Hackett Group Inc. (NASDAQ:HCKT) is trading at $15.72, after a 5.80% spike. Over the past month, the stock increased by 10.46%, and in the past year, by 2.11%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued. Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently under from its 52 week high by 10.73%. The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. View more earnings on HCKT Most often, an industry will prevail in a particular phase of a business cycle, than other industries. The Hackett Group Inc. has a better P/E ratio of 67.55 than the aggregate P/E ratio of 42.09 of the IT Services industry. Ideally, one might believe that The Hackett Group Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. There are many limitations to price to earnings ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings. See more from BenzingaClick here for options trades from BenzingaThe Hackett Group: Q4 Earnings InsightsEarnings Scheduled For February 23, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The Hackett Group: Q4 Earnings Insights
(Tue, 23 Feb 2021 22:05:40 +0000)
Shares of The Hackett Group (NASDAQ:HCKT) were flat after the company reported Q4 results. Quarterly Results Earnings per share were down 4.17% over the past year to $0.23, which beat the estimate of $0.21. Revenue of $59,281,000 decreased by 14.22% year over year, which beat the estimate of $56,820,000. Guidance Q1 EPS expected to be between $0.24 and $0.26. Q1 revenue expected between $61,000,000 and $63,000,000. How To Listen To The Conference Call Date: Feb 23, 2021 View more earnings on HCKT Time: 05:00 PM ET Webcast URL: https://www.thehackettgroup.com/# Price Action 52-week high: $17.61 52-week low: $9.50 Price action over last quarter: Up 1.30% Company Profile The Hackett Group Inc is a United States based advisory firm. The company's offerings include executive advisory programs, benchmarking, business transportation, and technology advisory services. The company's executive and practices advisory programs offer performance metrics, peer-learning opportunities, and practice implementation practices. The benchmarking services help organizations measure and assess internal efficiency and effectiveness. The business transformation programs help customers develop strategies to improve performance. The company's technology advisory services help clients improve decision-making capabilities and deploy software applications. The Hackett Group generates the majority of its revenue in the United States. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 23, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
LOJN LO-JACK CORP COM
SectorSecurity Systems & Services
RecommendationsBuy
Buy Near3.84
Stop Loss3.21
Posted Date2/8/2009 12:00:00 AM
First resistance5.33
Second resistance6.73
Third resistance7.20
First Support3.41
Second Support3.21
Comments
2/8/2009 12:42:24 PM0) LoJack Corporation (LOJN), the company that invented the stolen vehicle recovery market more than two decades ago, is the global leader in finding and recovering a wide range of mobile assets including cars, construction equipment and motorcycles having recovered more than $5 billion USD in stolen assets worldwide
1) In today's rapidly changing world, LoJacks core competencies are more valuable and more relevant than ever as they are now being applied into new areas, such as the prevention, detection and recovery of stolen cargo and finding and rescuing people with cognitive disorders such as Alzheimers and autism
2) LoJack has the proven processes, ultimate technology for recovery ,Radio Frequency and unique integration with law enforcement agencies, making its offerings the most effective solutions that not only deliver a wide range of recoveries, but also enhance the safety of the public on a global level
3) LoJacks Stolen Vehicle Recovery System operates in 26 states and the District of Columbia, and in more than 30 countries throughout North America, South America, Europe, Africa and Asia
4) This Penny Stock looks good candidate for portfolio investment
5) Before to invest Penny Stock understand your risk
6) To manage your risk keep tight stop loss on all investment.
LOJN
ANAD ANADIGICS Inc
SectorSemiconductors
RecommendationsBuy
Buy Near2.16
Stop Loss1.90
Posted Date2/8/2009 12:00:00 AM
First resistance2.55
Second resistance3.06
Third resistance3.92
First Support2.16
Second Support1.90
Comments
2/8/2009 12:45:38 PM0) ANADIGICS, Inc
1) is a provider of semiconductor solutions in the broadband wireless and wire line communications markets
2) The Company’s products include power amplifiers (PAs), tuner integrated circuits, active splitters, line amplifiers and other components, which can be sold individually or packaged as integrated radio frequency (RF) and front end modules This penny Stock closer to its strong support and looks good candidate for portfolio investment
3) Before to invest in penny Stock understand the risk factor
4) Due to market and economic condition keep tight stop loss on all investment.
ANAD
CHUX O CHARLEYS INC COM
SectorRestaurants
RecommendationsBuy
Buy Near2.66
Stop Loss1.96
Posted Date2/8/2009 12:00:00 AM
First resistance3.14
Second resistance5.44
Third resistance7.30
First Support2.05
Second Support1.23
Comments
2/8/2009 12:50:26 PM0) OCharleys Inc
1) is a casual dining restaurant company
2) The Company owns and operates three restaurant concepts under the OCharleys, Ninety Nine and Stony River Legendary Steaks trade names
3) As of December 30, 2007, it operated 229 OCharleys company owned restaurants in 16 states in the Southeast and Midwest, 115 Ninety Nine restaurants in nine Northeastern states, and ten Stony River restaurants in six states in the Southeast and Midwest OCharleys beats by $0.13, misses on revs Reports Q4 (Dec) loss of $0.15 per share, $0.13 better than the First Call consensus of ($0.28); revenues fell 5.7% year/year to $202.9 mln vs the $206.8 mln consensus The main difference here is that OCharleys would have still closed out its latest quarter in the red without writing down the value of its assets
4) This penny Stock closer to its strong support and looks good candidate for portfolio investment
5) Before to invest in any penny Stock understand your risk
6)
CHUX
ACTG Acacia Research Corporation
SectorTechnology : Electronic Instr. & Controls
RecommendationsBuy
Buy Near3.01
Stop Loss2.42
Posted Date1/1/2009 12:00:00 AM
First resistance3.61
Second resistance4.60
Third resistance5.55
First Support3.01
Second Support2.84
Comments
1/1/2009 8:55:19 PM0) Acacia Research Corporation (ACTG) has given a breakout with high volume and also given a buy signal, with rising moving average
1) Stockhastic, rate of change (ROC) and ADX also given a buy signal Acacia Research Corporation (ACTG) announced on Dec 31 2008 that its subsidiary, Data Network Storage LLC, Telematics Corporation, International Printer Corporation and Light Valve Solutions LLC has entered into a settlement and license agreement with the Hewlett-Packard Company relates to storage area networks, Datatrac Corporation, Océ, N.V
2) and Océ North America, Inc
3) and Hitachi, Ltd respectively
4) Recently Acacia Research Corporation (ACTG) bought the rights to a patent related to wireless data technology and its subsidiary, Acacia Patent Acquisition LLC, has acquired the rights to patents relating to vehicle occupant sensing technology.

As per technical analysis and fundamental research Acacia Research Corporation (ACTG) looks good candidate for penny Stock investing as well as you can add in portfolio investment
5) Recently ACTG given a breakout with rising moving average and also Stockhastic and Rate of change (ROC) given a buy signal
6) Acacia Research Corporation (ACTG) you can consider for Investment, Swing Trading, penny Stock Investing, Day trading
7) Due to market and economic condition keep tight stop loss on all position
8) You can buy Acacia Research Corporation (ACTG) near $3.01
ACTG
Woodford Sequel Begins With Assets That Led to His Downfall
(Tue, 16 Feb 2021 22:14:30 +0000)
(Bloomberg) -- Fallen stock picker Neil Woodford is mounting one of the most unusual comebacks in investment history: He’s seizing a second chance to manage a pool of assets at the center of his fund empire’s collapse.The manager has been picked by Acacia Research Corp. to run a portfolio of thinly traded holdings that the U.S. life sciences firm snapped up from Woodford’s former investors at bargain prices. The assets will make up the cornerstone of a new biotech-focused strategy that Woodford plans to open up to other institutional investors.In a departure from his former approach that made him a cult figure among mom-and-pop investors in the U.K., Woodford is steering clear of retail clients in his new incarnation. Woodford’s emphasis on unlisted and smaller quoted equities, many involved in biotech, eventually led to his undoing after he was unable to sell holdings to meet a mounting spate of withdrawals in 2019.With his plan to stage a revival, Woodford is attempting an ambitious feat that has eluded legendary money managers such as Bill Gross and Anthony Bolton. Gross, once feted as Pimco’s “Bond King” while running the world’s biggest mutual fund there, returned with a vehicle at Janus Henderson Group Plc that failed to beat its benchmarks before his 2019 retirement. Anthony Bolton, who like Woodford was a darling of U.K. retail investors while at Fidelity Investment International, sought to reinvent himself with a China-focused fund in a comeback lasting less than four years after performing poorly.“Woodford will always be a major red flag,” said Bev Shah, founder of City Hive, an advocacy group in London that promotes diversity in the investment management industry. “I would be curious to know how this new entity would pass due diligence of any institutional investor or asset owner.”Fund FreezeWoodford built his reputation by calling major swings in technology, tobacco and other stocks over two decades while at Invesco Ltd. He struck out on his own in 2014, taking many of his clients with him. Over time, Woodford started veering more into thinly traded, smaller companies -- a strategy that backfired when performance started faltering. As clients started to pull out in 2019, he was forced to freeze his LF Woodford Equity Income Fund because he couldn’t meet redemptions.In October 2019, he was ousted as manager of his flagship fund and announced he would shutter his investment firm, a stunning fall that counts as one of the most dramatic in London’s financial history. More than a year later, the money is still in the process of being returned to investors, who appear set to lose more than 1 billion pounds ($1.4 billion).Woodford will manage a familiar set of holdings as part of his new venture, including Immunocore, Oxford Nanopore Technologies Ltd. and Arix Bioscience Plc. Acacia purchased the portfolio for 224 million pounds from Woodford’s now-liquidated fund, and the holdings are now worth around 690 million pounds as many of them benefited from a rally in healthcare stocks during the pandemic, according to a person familiar with the matter. For Woodford’s former investors in the Equity Income Fund, though, the rebound comes too late: they’ve lost out on some 460 million pounds in returns from the rally after selling out at depressed prices.Call for ActionGina Miller, a campaigner on financial-services issues who runs her own investment firm called SCM Direct, waded into the fray after news of Woodford’s plan. She called on the chairman and members of the Treasury Select Committee to launch an independent probe into the collapse of Woodford’s fund. She also criticized an ongoing investigation by the U.K.’s Financial Conduct Authority as “woefully late and utterly meaningless”.“Too often the perpetrators of financial wrongdoing seem to slip off the hook, many to start up new lucrative operations while it is ordinary savers who suffer the brunt of this wrongdoing,” Miller said. “It ought to be a very serious source of public policy concern that high profile individuals such as Mr. Woodford can be allowed to re-commence trading, with the slate ostensibly wiped clean.”Woodford declined to comment. In an interview with the Telegraph published on Sunday, Woodford rejected criticisms of his approach and said the decision to liquidate the fund by the administrator -- Link Fund Solutions -- was more damaging to investors. The decision to liquidate the fund was “considered to be in the best interests of all investors,” a spokeswoman for Link said by email.The FCA said in a statement late Tuesday that its investigation was “progressing” but had been hampered by the pandemic. It had also contacted the Jersey regulator following reports that Woodford’s new business may operate from there.“In taking any decision on whether to authorize a firm, we consider whether it is ready, willing and organized to comply, on a continuing basis, with our requirements and standards,” Mark Steward, FCA’s director of enforcement and market oversight, said in the statement. “That includes, for example, the sustainability of the firm’s business model and the fitness of its management.”“Unmatched” InvolvementFor Acacia, the appeal is that Woodford is uniquely positioned to oversee the portfolio given his familiarity with the companies.“Neil Woodford has financed an extraordinary number of British life-sciences companies over the last 20 years” Clifford Press, Acacia’s chief executive officer, said in a statement. “The scope of his involvement with these companies is unmatched in the U.K.”While he has experience in the U.K. life sciences industry, the new strategy is a move away from an approach that vaulted him to fame earlier in his career, with big picks like AstraZeneca Plc and British American Tobacco Plc. And not everyone is convinced that Woodford will be successful in winning a big base of new investors.“Biotech is very exciting but it has quite a narrow constituency,” Stuart MacDonald, who helps funds raise money as managing partner at Bride Valley Partners, said. “Is this where you would go if you want an exposure to this space in the first place?”(Updates with FCA comment in 12th paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
What You Need To Know About Acacia Research Corporation's (NASDAQ:ACTG) Investor Composition
(Sat, 23 Jan 2021 06:03:25 +0000)
A look at the shareholders of Acacia Research Corporation ( NASDAQ:ACTG ) can tell us which group is most powerful...
Is ACTG A Good Stock To Buy Now?
(Fri, 11 Dec 2020 23:23:12 +0000)
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]
Acacia Research Corp. to Host Earnings Call
(Mon, 09 Nov 2020 14:30:00 +0000)
NEW YORK, NY / ACCESSWIRE / November 9, 2020 / Acacia Research Corp.
Acacia Research: Q3 Earnings Insights
(Mon, 09 Nov 2020 13:49:15 +0000)
Shares of Acacia Research (NASDAQ:ACTG) remained unaffected after the company reported Q3 results.Quarterly Results Earnings per share rose 313.33% year over year to $0.32, which beat the estimate of ($0.02).Revenue of $19,466,000 rose by 1037.70% year over year, which beat the estimate of $400,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Nov 09, 2020View more earnings on ACTGTime: 11:00 AMET Webcast URL: https://www.webcaster4.com/Webcast/Page/2371/38302Recent Stock Performance Company's 52-week high was at $4.46Company's 52-week low was at $1.75Price action over last quarter: down 12.44%Company Overview Acacia Research Corp is engaged in the acquisition, development, and patents technologies through its subsidiaries. It assists patent owners with the prosecution and development of their patent portfolios; protection of their patented inventions from unauthorized use; generation of licensing revenue from users of their patented technologies; and enforcement against unauthorized users of their patented technologies.See more from Benzinga * Click here for options trades from Benzinga * WhiteHorse Finance: Q3 Earnings Insights * Recap: Hemisphere Media Q3 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
LAB LABRANCHE & CO INC COM
SectorFinancial
RecommendationsBuy
Buy Near6.23
Stop Loss4.72
Posted Date11/2/2008 12:00:00 AM
First resistance7.43
Second resistance7.98
Third resistance11.80
First Support5.70
Second Support4.72
Comments
11/3/2008 12:00:04 AM0) LaBranche & Co Inc.com (LAB)Stocks given a double top breakout on 10/31/08 with good volume again many technical indicators also have given a buy signal, with rising moving average
1) Stockhastic and ADX also given a buy signal
2) LaBranche & Co Inc.com (LAB) is a Stock-exchange specialist firm
3) As per technical analysis and fundamentally LaBranche & Co Inc.com (LAB) look good candidate for portfolio investment. LaBranche & Co Inc.com you can consider for Investment, Swing trading, Stock trading, penny Stock Investing, Day trading
4) Due to market and economic condition keep tight stop loss on all position
5) You can buy LaBranche & Co Inc.com (LAB) near $6.23
LAB


Next Page >>   

 

























Home for ۩ Day Trading | Breakout Stock trading system | Penny Stock Investing | Market Research

Contact Us | Affiliate | Disclaimer | Feedback | Help | Site Map | RSS  RSS
All Rights Reserved © 2000-2006 Flyingstock.com
Penny Stock picks for Stock trading Penny Stock investing support resistance

This Service is solely an information service provided by the automated software tool & is for entertainment purposes only. It should be understood that there is no guarantee that past performance of our stock trading system or day trading Strategy or Penny stock picks will be indicative of future results.